title: Nelfinavir potency concerns.
abstract: Results from several recent studies may help clarify how to best use anti-HIV drugs as part of first line therapy. These results seem to suggest that nelfinavir (Viracept), the most widely used protease inhibitor, may not be as potent as other drugs in its class or some of the non-nucleoside RT inhibitors (NNRTIs). This article provides an overview of the studies.
mesh_terms: D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019888:Nelfinavir / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D018894:Reverse Transcriptase Inhibitors; D019888:Nelfinavir